Division of Cardiology, Jersey Shore Medical Center, Neptune, NJ, USA.
Division of Cardiology, Houston Methodist Hospital, Houston, TX, USA.
Curr Cardiol Rep. 2022 Jun;24(6):653-657. doi: 10.1007/s11886-022-01684-7. Epub 2022 Mar 30.
The ISCHEMIA trial demonstrated no difference in myocardial infarction or death in patients with stable coronary disease and moderate or large ischemia territory treated either with invasive revascularization or optimal medical therapy. Whether the findings of the randomized control trial relates to real-world outcomes is uncertain.
Contemporary guideline-directed medical therapy has had a significant impact on the prognosis of coronary artery disease. Various observational data appear to indicate limited generalizability of the ISCHEMIA trial in different populations. Further studies are warranted to evaluate the optimal modality of therapy in patients with stable coronary disease and moderate or severe ischemia. The applicability of ISCHEMIA and ISCHEMIA-CKD trials still requires further validation.
ISCHEMIA 试验表明,对于稳定型冠心病伴中度或大面积缺血区的患者,采用有创血运重建或最佳药物治疗,心肌梗死或死亡发生率无差异。随机对照试验的结果是否与真实世界的结果相关尚不确定。
目前,指南指导的医学治疗对冠状动脉疾病的预后有重大影响。各种观察性数据似乎表明,ISCHEMIA 试验在不同人群中的推广应用具有一定局限性。需要进一步研究来评估稳定型冠心病伴中度或重度缺血患者的最佳治疗方式。ISCHEMIA 和 ISCHEMIA-CKD 试验的适用性仍需要进一步验证。